• Image 01
  • Image 02
  • Image 03
  • Image 04
  • Image 05
  • Image 06
Need assistance? Contact Us: 1-800-255-5897

Menu

  • Home
  • About Us
    • Company Overview
    • Management Team
    • Board of Directors
  • Your Loan Service Center
  • MAKE A PAYMENT
  • Business Service Center
  • Contact Us
  • Home
  • About Us
    • Company Overview
    • Management Team
    • Board of Directors
  • Your Loan Service Center
  • MAKE A PAYMENT
  • Business Service Center
  • Contact Us
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

(CSE:BNXT)

0.2850 -0.0150 (-5.00%)
Delayed Quote Updated: 3:56 PM EDT, Oct 19, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 112,636
Open 0.2900
Bid (Size) 0.2700 (1,500)
Ask (Size) 0.3000 (4,500)
Prev. Close 0.3000
Today's Range 0.2700 - 0.2900
52wk Range 0.2700 - 0.8700
Shares Outstanding N/A
Dividend Yield N/A
Chart for  (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
News headline image
BioNxt Completes GMP Manufacturing and Submits Clinical Trial Application for Sublingual Cladribine Drug Candidate
October 19, 2026
From BioNxt Solutions Inc.
Via ACCESS Newswire
News headline image
BioNxt Advances Sublingual Everolimus ODF for Organ Transplant Rejection with Initiation of Large-Animal Pharmacokinetic Study
September 08, 2026
From BioNxt Solutions Inc.
Via ACCESS Newswire

Performance

52-Week Range 67.2% below 52-week high
0.2850
0.2752W Low 0.8752W High
1 Week 12.3% below 1-week high
0.271W Low 0.331W High

(BNXT) traded between $0.27 and $0.87 over the past 52 weeks and last traded at $0.28, 67.2% below its 52-week high. Over the past week it ranged between $0.27 and $0.33.

Past 12 Months
-5.0%
-30.5%
+1.8%
-36.7%
-56.2%
-64.4%
1W -$0.02
1M -$0.12
3M +$0.00
6M -$0.17
YTD -$0.37
1Y -$0.52

BNXT was -64.4% over the past year, -36.7% over six months, -56.2% year to date, -5.0% in the last week.

12 Months vs Market
BNXT
-64.4%
DIA
+11.1%
SPY
+14.2%
QQQ
+17.5%
IWM
+9.3%

Over the past 12 months BNXT returned -64.4% versus DIA (Dow) +11.1%, SPY (S&P 500) +14.2%, QQQ (Nasdaq 100) +17.5% and IWM (Russell 2000) +9.3%.

Volume & Liquidity 3.42× 3-mo avg
Today 112,636 3-mo avg 32.9K
1W
40.8K
1M
30.0K
3M
32.9K
6M
25.4K
YTD
41.8K
1Y
50.6K

BNXT most recently traded 112,636 shares against a 3-month average daily volume of 32.9K.

More News

Read More
News headline image
BioNxt Advances Cladribine Clinical Program with Completion of the Investigational Medicinal Product Dossier (IMPD) Ahead of Human Clinical Studies
August 19, 2026
From BioNxt Solutions Inc.
Via ACCESS Newswire
News headline image
BioNxt Provides Development, Intellectual Property and Commercial Update Across Sublingual Drug Delivery Pipeline
August 17, 2026
From BioNxt Solutions Inc.
Via ACCESS Newswire
News headline image
BioNxt Provides Development, Intellectual Property and Commercial Update Across Sublingual Drug Delivery Pipeline
August 04, 2026
From BioNxt Solutions Inc.
Via ACCESS Newswire
News headline image
BioNxt Advances GLP-1 Sublingual Semaglutide ODF Program with Next Stage of Delivery Development Underway
July 06, 2026
From BioNxt Solutions Inc.
Via ACCESS Newswire
News headline image
BioNxt Engages Business Development & Licensing Advisors for Commercialization of Patented Sublingual Cladribine ODF
June 15, 2026
Via ACCESS Newswire
News headline image
BioNxt Advances Semaglutide ODF Program into Active Pharmaceutical Development
May 19, 2026
Via ACCESS Newswire
News headline image
BioNxt Applies Advanced Drug Delivery Strategy and Psychedelic Compound Library to Emerging Therapeutics Market Amid Accelerating Global Momentum
April 28, 2026
Via ACCESS Newswire
News headline image
BioNxt Initiates GMP Manufacturing of Clinical-Grade Sublingual Cladribine Film Targeting Multiple Sclerosis (MS)
April 14, 2026
Via ACCESS Newswire
News headline image
BioNxt Secures Unitary European Patent for Sublingual Cladribine ODF Platform Across 18 Countries
April 07, 2026
Via ACCESS Newswire
News headline image
BioNxt Advances Semaglutide as First Application of Broad GLP-1 ODF Platform Strategy
March 30, 2026
Via ACCESS Newswire
News headline image
BioNxt Enters Commercialization Phase with Global Patent Protection and U.S. Fast Track Strategy for Sublingual Drug Delivery Platform
March 24, 2026
Via ACCESS Newswire
News headline image
BioNxt Signs Strategic Agreement for Eurasian Commercialization Following Cladribine ODF Patent Grant in Eurasia and Europe
March 17, 2026
Via ACCESS Newswire
News headline image
BioNxt Receives Milestone EPO Decision to Grant European Patent for Sublingual Cladribine Drug Delivery Technology for Multiple Sclerosis
February 17, 2026
Via ACCESS Newswire
News headline image
BioNxt Secures Innovative Chaperone Technology to Enhance Oral Thin-Film Drug Delivery
February 05, 2026
Via ACCESS Newswire
News headline image
BioNxt Reports Final Preclinical Results Demonstrating Approximately 40% Higher Cladribine Delivery for the Treatment Multiple Sclerosis (MS)
January 21, 2026
Via ACCESS Newswire
News headline image
BioNxt Reports Successful Final In-Vivo Dosing Study Results Supporting Superior Bioavailability of Cladribine Sublingual ODF
January 19, 2026
Via ACCESS Newswire
News headline image
Over 40% of Adults Struggle to Swallow Pills - BioNxt Targets a Global Adherence Problem with Rapid-Dissolving Thin-Film “Melt-in-Your-Mouth” Therapies
December 17, 2025
Via ACCESS Newswire
News headline image
BioNxt Advances "Melt in Your Mouth" Cladribine Formulation to Improve Treatment for MS Patients with Dysphagia
December 09, 2025
Via ACCESS Newswire
News headline image
BioNxt Signs Letter Agreement to Acquire 100% Interest in IP and to Codevelop a Sublingual Drug Formulation for Chemotherapy and Immunosuppressant Treatments
December 01, 2025
Via ACCESS Newswire
News headline image
BioNxt Secures Final Patent Grant from the Eurasian Patent Organization for Sublingual Cladribine Platform
November 20, 2025
Via ACCESS Newswire
News headline image
BioNxt Reports “Intention to Grant” Patent Notification from the European Patent Office for Its Oral Cladribine Sublingual Thin-Film as the Multiple Sclerosis Market Shifts Toward Patient-Friendly Therapies
November 04, 2025
Via PressReach
Topics Intellectual Property
News headline image
BioNxt Reports "Intention to Grant" Patent Notification from the European Patent Office for Its Oral Cladribine Sublingual Thin-Film as the Multiple Sclerosis Market Shifts Toward Patient-Friendly Therapies
November 04, 2025
Via ACCESS Newswire
News headline image
BioNxt Reports “Readiness to Grant” Patent Notification from the Eurasian Patent Organization
October 30, 2025
Via PressReach
Topics Intellectual Property

Frequently Asked Questions

Is BNXT publicly traded?
Yes, BNXT is publicly traded.
What exchange does BNXT trade on?
BNXT trades on the Canadian Securities Exchange
What is the ticker symbol for BNXT?
The ticker symbol for BNXT is BNXT on the Canadian Securities Exchange
What is the current price of BNXT?
The current price of BNXT is 0.2850
When was BNXT last traded?
The last trade of BNXT was at 10/19/26 03:56 PM ET
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.

Having difficulty making your payments? We're here to help! Call 1-800-255-5897

Copyright © 2019 Franklin Credit Management Corporation
All Rights Reserved
Contact Us | Privacy Policy | Terms of Use | Sitemap